Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demandLAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling ...

CHICAGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its subsidiary, SkyPharm S.A., has entered into an exclusive distribution agreement, dated as of September 28, 2025, with Diyar United for the marketing and sale of its Sky Premium Life® line of nutraceuticals in Kuwait. Diyar United is a respected distributor in Kuwait with extensive healthcare experience. Its stro ...

Core Insights - Cosmos Health Inc. is at a pivotal moment, having refined its strategy and operations to foster sustainable growth and long-term value creation [1][3] - The company aims to create a global healthcare platform integrating various sectors, including pharmaceuticals, nutraceuticals, and digital finance [4][5] - The ambition for 2030 is to transform into a global powerhouse by scaling branded products and leveraging AI and blockchain technologies [6][7] Vision & Ambition - The company has aligned all business units towards a common goal of making high-quality healthcare accessible globally [4][5] - Cosmos Health emphasizes resilience, creativity, and leadership in rapidly evolving industries [5] Milestones & Achievements - Significant progress has been made in financing, manufacturing capabilities, and innovation pipeline, including securing a $300 million financing facility [9][11] - The company has expanded its manufacturing footprint and strengthened its wholesale operations [10][18] Financial Performance & Outlook - In 2024, Cosmos Health reported revenues of approximately $54.43 million, a 2% increase from 2023, with a notable reduction in operating expenses [40][41] - The company aims for continued growth and profitability, targeting approximately $155.8 million in revenue by 2027 [48][44] Strategy & Roadmap - The growth strategy is built on six pillars, focusing on profitability, cash flow, and scaling high-margin businesses [46] - The company is committed to maintaining financial strength while pursuing innovation and global expansion [49][52] R&D and Innovation - Cosmos Health is advancing its proprietary obesity treatment, CCX0722, and expanding its R&D pipeline across multiple therapeutic areas [25][30] - The company utilizes its AI-enabled platform, Cloudscreen, to enhance drug discovery and accelerate innovation [26][50] Global Expansion - The flagship brand, Sky Premium Life, is expanding internationally, with over 150 premium products and strong demand across various regions [18][19] - The company has established a dual manufacturing hub in the U.S. and Europe to enhance supply chain resilience [18][22] Insider Commitment - The CEO has invested over $18 million of personal capital into the company, demonstrating a strong alignment of interests with shareholders [34][35] Sustainability Commitment - Cosmos Health is focused on balancing growth with social responsibility, emphasizing innovation, market development, and digital asset strategies [53][54]

当前，亚洲乃至全球市场对健康与预防性保健产品的需求显著上升。然而，行业在迎来机遇的同时，也 面临国际竞争加剧、研发成本高企与法规合规等多重挑战。在此背景下，Vitafoods Asia作为覆盖全产 业链的重要国际平台，为亚太企业把握趋势、对接资源提供了关键支持。 展会期间，Mom's Garden通过专业讲解、互动体验与商务洽谈，与来自东南亚、日韩等地区的客户及 合作伙伴进行了深入沟通，分享其基于亚太消费者体质所研发产品的科学理念与市场经验。品牌主推 的"0泻药"理念及相关产品——百草园清清片与百草园AKK益生菌，成为展台焦点。 2025年9月17日至19日，亚洲营养健康产业盛会——泰国国际营养保健食品展(Vitafoods Asia 2025) 在曼谷国家会议中心举行。德国成人高端膳食营养品牌Mom's Garden携专为亚太消费者研发的"0泻 药"肠道健康解决方案亮相，其科学理念与创新产品引发国际客户与行业伙伴广泛关注。 通过胃肠双区靶向释放系统，实现秋葵提取物与益生菌的分区精准释放，从而帮助缓解便秘；百草园 AKK益生菌则引入"新一代明星菌"，通过修复肠道4层屏障，帮助实现每天规律排便、减少糖油吸收， ...

Core Viewpoint - Cosmos Health Inc. has officially launched its U.S. operations with the introduction of its proprietary Sky Premium Life food supplements brand, marking a significant milestone in its expansion strategy into the world's largest nutraceuticals market [1][7]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [8]. - The company operates through subsidiaries in Europe and North America, focusing on manufacturing pharmaceuticals, food supplements, cosmetics, and medical devices [8]. Product Launch and Sales - The Sky Premium Life NOOR Collagen product, formulated with premium marine collagen tripeptide, is now available in the U.S. and is designed to support skin and joint health [3][5]. - Early sales momentum for NOOR Collagen is encouraging, with projections indicating it could generate over $12 million in annualized revenue [5][7]. Market Potential - The U.S. nutraceuticals market was valued at $163.7 billion in 2024 and is expected to grow at a CAGR of 6.2% through 2030, driven by increasing health awareness and demand for natural wellness solutions [6]. - The company anticipates strong gross margins of approximately 75% from its U.S. operations, indicating significant cash flow generation potential [5]. Strategic Commitment - Cosmos Health emphasizes its commitment to regulatory excellence and product integrity by manufacturing all Sky Premium Life products in GMP-certified, FDA-registered U.S. facilities [2]. - The launch of NOOR Collagen is the first step in a series of planned product introductions aimed at meeting strong consumer demand in the U.S. market [8].

Core Insights - Healthy Extracts Inc. has been invited to present at the ArcStone-Kingswood Growth Summit on September 18, 2025, in Toronto, Ontario [1] - The summit features over 20 high-growth companies and aims to facilitate strategic networking and insight-sharing among institutional and retail investors [1] Company Overview - Healthy Extracts Inc. operates as a platform focused on acquiring, developing, manufacturing, and marketing science-based nutraceuticals and oral delivery systems [1] - The company's products are targeted towards brain, heart, and metabolic health [1] Industry Context - The ArcStone-Kingswood Growth Summit 2025 is designed to connect high-growth companies with investors, highlighting the importance of networking in the nutraceuticals sector [1]

Group 1 - ProText Mobility, Inc. has had the "caveat emptor" designation removed and is now current in its corporate filing information, achieving OTCID Basic Market status [1] - The company specializes in the research, testing, and development of highly bioavailable botanical products using proprietary live plant extraction technology for nutraceutical and pharmaceutical applications [2]

Core Viewpoint - Gelteq Limited has successfully transitioned from research and development to active commercialization in the U.S. market through its collaboration with Healthy Extracts, marking a significant milestone for the company [2][3]. Company Overview - Gelteq Limited, headquartered in Melbourne, Australia, specializes in developing gel-based oral delivery solutions for various applications, including prescription drugs, nutraceuticals, pet care, and sports nutrition [4]. - The company's proprietary formulation technology addresses challenges in conventional drug delivery, such as taste masking, swallowing difficulties, and precision dosing [4]. Recent Developments - Healthy Extracts has launched products utilizing Gelteq's proprietary gel technology, which are the first to reach Gelteq's U.S. warehousing facility [2]. - The partnership with Healthy Extracts has evolved from initial warehousing and fulfillment arrangements to active sales and distribution, indicating growing momentum for Gelteq's gel delivery system [3]. Market Potential - The development highlights the growth potential of Gelteq's technology in large-scale wellness markets in the U.S. and its capability to meet consumer demand for innovative and clinically-informed products [2]. - The collaboration is expected to pave the way for additional products and partnerships in the U.S. market, enhancing Gelteq's presence and opportunities [3].

Core Insights - Jiva Technologies Inc. reported significant financial improvement for the fiscal year ended March 31, 2025, with revenue of CAD 4,600,991 and a reduced net loss of CAD 651,981 compared to a net loss of CAD 3,303,242 in the previous year [2][3] - The company has implemented a disciplined approach to cost management, resulting in substantial reductions in various expenses, which has positively impacted its financial performance [3][8] Financial Performance - Revenue for the year ended March 31, 2025, was CAD 4,600,991, with a net loss of CAD 651,981, a significant improvement from the previous year's loss of CAD 3,303,242 [2] - Loss per share improved to CAD 0.45 from CAD 3.99 in fiscal 2024, indicating a narrowing of losses [2] - Operating cash flow improved to CAD (873,632) from CAD (1,079,014) in 2024, showcasing better working capital management [8] Cost Management - Advertising and promotion expenses decreased by 84% compared to 2024, reflecting a shift to more cost-efficient marketing channels [8] - Consulting, legal, and salary expenses also saw significant declines, contributing to the overall reduction in operational costs [8] Strategic Positioning - Jiva Technologies is well-positioned for growth in the wellness technology sector, leveraging its unique platform that combines e-commerce technology, immersive wellness environments, and digital communities [6][7] - The company is actively pursuing joint ventures to enhance its online presence and support wellness brands, including a recent partnership with LIV3 for SugarShield [9] Operational Highlights - The company achieved a gross margin of 64% in Q1 2025, consistent with the previous quarter [8] - Operating income for 2025 was CAD 170,000 compared to an operating loss of CAD 278,000 in 2024, driven by lower operating expenses [8] - As of June 30, 2025, the cash balance was CAD 196,000, indicating a strengthened financial position [8]

Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and focuses on the R&D of novel patented nutraceuticals and innovative OTC products [6] Recent Developments - Cosmos Health's subsidiary, Sky Pharm SA, signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman [1][3] - Scientific Pharmacy is a leading healthcare and beauty company in Oman, known for its strong customer focus and international brand partnerships [2] - The agreement includes an initial purchase order of 42,000 units, with Scientific Pharmacy managing all core activities related to the distribution and marketing of the products [3] Market Insights - The GCC nutraceuticals market was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033, with a compound annual growth rate (CAGR) of 8.7% [4] - Growth in the nutraceuticals market is driven by rising health awareness, higher disposable incomes, government initiatives addressing lifestyle diseases, rapid urbanization, and the expansion of retail and e-commerce channels [4] Strategic Outlook - The CEO of Cosmos Health expressed excitement about the expansion into Oman, highlighting the potential for significant revenue generation supported by Scientific Pharmacy's established network [5] - The agreement is seen as a milestone that showcases the quality of Cosmos Health's products and the increasing global demand for the Sky Premium Life brand [5]